Mandate

Vinge advises RusForest in connection with inter alia rights issue

September 24, 2010

RusForest carries out a rights issue amounting to approximately SEK 440 million, proposes authorisation for an issue in kind to enable acquisition of shares in companies within Nord Timber Group and acquires a majority stake in LDK-3, both companies with operations in the city of Arkhangelsk in North West Russia.

The rights issue and in kind authorisation are subject to resolutions at an extraordinary general meeting to be held on 8 October 2010 and the LDK-3 acquisition is contingent on inter alia Russian anti-monopoly approval, which is expected to be attained before the end of the year. The transactions are prompted by a capital need to facilitate the development of RusForest’s existing operations in Ust Ilimsk, Magistralny and Boguchany as well as enable RusForest’s expansion into North West Russia, which are central steps in RusForest’s development plan to become Russia’s leading independent forestry and sawmilling company.

Vinge has assisted RusForest in questions relating to Swedish law and Vinge’s team has primarily consisted of Göran Nyström, Jesper Schönbeck, Dain Nevonen, Jonas Johansson and Christian Granqvist.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025